Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Duloxetine
Drug ID BADD_D00734
Description Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686.[A178741] Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder.[L6454] It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.
Indications and Usage **Indicated** for: 1) Management of Major Depressive Disorder.[label] 2) Management of Generalized Anxiety Disorder.[label] 3) Management of diabetic peripheral neuropathy.[label] 4) Management of fibromyalgia.[label] 5) Management of chronic musculoskeletal pain.[label] 6) Management of osteoarthritis of the knee in adults.[L6364] 7) Management of chronic lower back pain in adults.[L6364] 8) Management of stress urinary incontinence in adult women.[L6367] **Off-label** uses include: 1) Management of chemotherapy-induced peripheral neuropathy.[A178603] 2) Management of stress urinary incontinence in adult men after prostatectomy until recovery is complete.[L6370]
Marketing Status approved
ATC Code N06AX21
DrugBank ID DB00476
KEGG ID D07880
MeSH ID D000068736
PubChem ID 60835
TTD Drug ID D01AXB
NDC Product Code 49252-007; 50268-269; 50268-270; 51655-237; 55700-605; 61919-422; 63629-5174; 65841-799; 71205-358; 71205-445; 71205-525; 71205-602; 31722-582; 47335-616; 47335-617; 50268-286; 0228-2892; 60760-559; 70518-1054; 71205-005; 71610-403; 27241-098; 31722-170; 43547-380; 43547-381; 47335-382; 47335-619; 55700-628; 60760-462; 61919-483; 67877-264; 68084-692; 68180-295; 68180-296; 55700-727; 63629-5202; 70518-2630; 76420-236; 31722-169; 47335-383; 47335-618; 49252-009; 50090-6406; 55154-4981; 63629-8051; 63629-8748; 68180-294; 68180-297; 70518-1128; 70518-1139; 70518-3287; 70710-1538; 27241-164; 50268-287; 53002-1494; 60760-461; 65841-801; 67877-265; 70518-2855; 71335-1672; 71335-1964; 46708-278; 68071-2709; 68084-683; 68382-387; 70518-3601; 71335-0402; 71335-2017; 27241-097; 27241-099; 31722-168; 49252-008; 0228-2891; 53002-1561; 68788-7672; 70710-1539; 70771-1344; 70771-1346; 80425-0311; 65977-0035; 46708-280; 47335-381; 50090-6040; 65841-800; 68382-385; 68788-7935; 70710-1537; 70771-1345; 80425-0119; 31722-581; 46708-279; 50090-6281; 50268-288; 55154-4980; 67877-263; 68084-675; 68382-386; 70518-1011; 70518-3177; 31722-583; 43547-379; 45865-813; 50090-4708; 50090-5940; 50268-271; 0228-2890
UNII O5TNM5N07U
Synonyms Duloxetine Hydrochloride | Hydrochloride, Duloxetine | Duloxetine HCl | HCl, Duloxetine | LY 248686 | LY-248686 | LY248686 | Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987 | LY 227942 | LY-227942 | LY227942 | Duloxetine | N-methyl-3-(1-naphthalenyloxy)-3-(2-thiophene)propanamide | N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine | Duloxetine, (+)-isomer | Cymbalta
Chemical Information
Molecular Formula C18H19NOS
CAS Registry Number 116539-59-4
SMILES CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sleep sex17.15.02.008; 19.02.03.0110.000027%-
Stiff person syndrome10.04.10.017; 15.05.04.021; 17.05.02.0180.000173%-
Neonatal behavioural syndrome15.05.04.020; 17.02.05.058; 18.04.04.010; 22.11.02.0070.000040%-
Thunderclap headache17.14.01.0180.000040%-
Intensive care unit acquired weakness15.05.05.012; 17.09.01.0040.000053%-
Rapid eye movement sleep behaviour disorder17.15.04.008; 19.02.03.0100.000240%-
Selective eating disorder14.03.02.024; 19.09.01.0120.000144%-
Central sleep apnoea syndrome17.15.05.002; 19.02.05.011; 22.02.01.0350.000067%-
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.002---
Electric shock sensation08.06.02.023; 17.02.07.0240.000234%-
Fumbling17.01.02.0300.000027%-
Gait inability08.01.02.011; 17.02.05.0690.000152%-
Hepatic cytolysis09.01.07.0360.000027%-
Histrionic personality disorder19.05.03.001---
Immune thrombocytopenia01.08.01.013; 10.02.01.083---
Inadequate analgesia08.06.01.040; 12.02.20.0060.000091%-
Inhibitory drug interaction08.06.03.0140.000059%-
Intestinal prolapse07.11.01.0140.000027%-
Lung opacity22.12.01.0060.000027%-
Lymphocytic oesophagitis01.02.05.004; 07.08.05.0080.000040%-
Neonatal seizure17.12.03.038; 18.04.04.0190.000040%-
Oesophageal hypomotility07.02.02.0210.000040%-
Paedophilia19.08.06.0030.000027%-
Pharyngeal swelling22.04.05.028---
Psychotic symptom19.03.01.0120.000040%-
Spinal stenosis15.10.04.014; 17.10.01.0310.000027%-
Taste disorder07.14.03.004; 17.02.07.029---
Therapeutic product effect decreased08.06.01.0500.000533%-
Therapeutic product effect delayed08.06.01.0510.000059%-
Therapeutic product ineffective08.06.01.0570.000104%-
The 20th Page    First    Pre   20 21    Next   Last    Total 21 Pages